4 Underappreciated Biotech Stocks You Should Consider in 2018

Biotechnology might be one of the most peculiar stock investments in the market due to its ambivalent nature. As investing in biotech stocks can bring traders double of what they have invested, a single bad factor in the market can make severe losses, going even towards losing 90% of what you have originally invested.

With biotechnology companies, even though investing in stocks is enabled, it is often the case that these companies end up without a final product or a service after spending millions on researching and investments.

That is why investing in biotech stocks should be probably done with precaution. However, in case you are looking for biotech stocks to invest in, we are presenting 4 underappreciated biotech stocks that should be considered in 2018 and potentially beyond the current year.

Biotech Stock #1: KAMADA (NASDAQ: KMDA)

Kamada is an Israeli based company founded back in 1990, with a subsidiary company called Kamada Assets Ltd. founded in 2001. Kamada is focused on designing and manufacturing plasma-derived protein therapeutics for orphan diseases.

Kamada can’t be exactly called underappreciated since it has a year to date gains go up to 12.4% with 39 times forward earnings and 18 times trailing earnings. So, if KMDA stocks are performing in a decent manner for the past year, how come it is ranked as unappreciated?

The answer is simple: not many traders seem to be interested in KAMADA biotech stocks, even though it has been performing well on a year to date basis.

The lack of interest might be the definitive factor to have lowered the value of these biotech stocks, which is easily seen through the lowered volumes of shares, showing barely 5500 shares at the current moment.

Moreover, KAMADA makes up for a drug manufacturer with a long and successful history in the industry of biotechnology, also carrying minor debts when compared to its revenue with near-steady revenue growth and profitable margins.

The reason why KMDA is not ranked highly at this moment is the fact that its stocks could turn passive. However, it surely deserves to be kept close attention to.

Biotech Stock #2: Gilead Sciences (NASDAQ: GILD)

Gilead Sciences Inc. is a biopharmaceutical company focused on research, discovery, and commercialization of innovative medicines. Gilead Sciences Inc. holds the revenue of 26.11 billion dollars making it a serious player in the biotechnology industry.

However, as more than several biotech stocks plummeted at the beginning of this year, GILD makes up for one of those stocks, making it an underappreciated biotech stock despite the potential it holds.

To make things worse for GILD, the stocks were performing well in the market until the fallout in January of 2018, with the resignation of Gilead’s CEO and the fall of revenues for hepatitis C drug by over 60%.

Still, GILD has proper profitability margins, making it eligible for a close watch.

Biotech Stock #3: AbbVie (NYSE: ABBV)

AbbVie Inc. is a development and research pharmaceutical company with acquiring a massive momentum with one of their most popular drugs, Humira.

Humira is designed to remove and diminish, as well as ease the pain and inflammation caused by autoimmune diseases and conditions, also bringing decent profit to the company, which also makes it a desirable biotech stock.

In the course of 6 years since Humira was officially released as ready for patients, AbbVie showed a significant revenue growth from 7.9 billion dollars to over 18 billion dollars only on selling and distributing Humira, gaining 15% of the rise in revenues.

However, although Humira stands for a pharmaceutical gainer, ABBV stocks still seem to be experiencing a lack of interest with only 4.6% of rise from year to date.

Biotech Stock #4: Geron (NASDAQ: GERN)

Geron Corporation is a public biotechnology company specialized in manufacturing and developing therapeutics for cancer with telomerase inhibition, specialized in oncology.

GERN stocks might actually be the best-performing stocks on the list based on the year to date revenue describing an amazing pace of growth of 113%. Geron also made partners with Johnson and Johnson in order to develop and commercialize a special treatment for hematologic myeloid malignancies.

However, the company is still very young when it comes to its market capitalization that carries 720 million dollars in oppose to similar biotechno0logy companies that are holding dozens of billions of dollars in revenue.

Moreover, in case the mentioned treatment turns out to be a success, Geron can gain a lot of momentum regarding Johnson and Johnson partnership, which means that GERN stocks might be taken over the potentially positive influence.

Want to learn more about the Stock Market & Trading Stocks or need a Mentor & Success Coach? Make sure to follow the iStreetWire / iStreetWirePRO Head Coach & Founder Chad Curtis, a 19+ Year Stock Market Veteran, Super Business & Success Coach, Entrepreneur & Investor Specializing in Day Trading, Swing Trading and Short-Term Investing in Stocks Under $20. He Coaches, Teaches and Mentors new and or experienced Traders, Investors, Individuals, Entrepreneurs & Business Owners.

Make sure to Join Chad Curtis now at this FREE Live Trading Chat room t.me/iStreetWire and make sure to sign up to  www.istreetwirepro.com.

You can also follow Chad Curtis on social media at:
Twitter: www.twitter.com/iStreetWire
Instagram: www.instagram.com/istreetwire

Three Movers to Watch for: Geron Corporation (GERN), Xylem Inc. (XYL), Kratos Defense & Security Solutions, Inc. (KTOS)

Geron Corporation (GERN) retreated with the stock falling -0.83% or $-0.02 to close at $2.4 on light trading volume of 1.29M compared its three months average trading volume of 1.3M. The Menlo Park California 94025 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -16.96% down for the period and up by 15.94% so far this year. With price target of $4.38 and a 32.6% rebound from 52-week low, Geron Corporation has plenty of upside potential, making it a hold with a view buy.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Xylem Inc. (XYL) gained $0.02 to close the day at a new closing price of $47.67, a 0.04% increase in value from its previous closing price that moved the stock 32.69% above its 52 week low of $36.42. A total of 1.29M shares exchanged hands during the day compared with its three month average trading volume of 1.51M. The stock, which fluctuated between $47.37 and $47.94 during the day, currently situated -12.99% below its 52 week high. The stock is down by -0.73% in the past one month and down by -10.13% over the past three months. With a one year target estimate of $54.31 and RSI of 42.63, the stock still has upside potential, making it a hold for now.

Xylem Inc. engages in the design, manufacture, and application of engineered technologies for the water and wastewater applications. It operates through two segments, Water Infrastructure and Applied Water. The Water Infrastructure segment offers various products, including water and wastewater pumps, treatment and testing equipment, and controls and systems, as well as filtration, disinfection, and biological treatment equipment under the Flygt, WEDECO, Godwin, WTW, Sanitaire, YSI, and Leopold names for the transportation, treatment, and testing of water and wastewater for public utilities and industrial applications. The Applied Water segment provides pumps, valves, heat exchangers, controls, and dispensing equipment systems under the Goulds Water Technology, Bell & Gossett, A-C Fire Pump, Standard Xchange, Lowara, Jabsco, Flojet, and Flowtronex names for residential and commercial building services, industrial water, and irrigation applications. Xylem Inc. also provides smart metering, network technologies and advanced data analytics to water, gas, and electric utilities. The company markets and sells its products through a network of direct sales force, resellers, distributors, and value-added solution providers in the United States, Europe, the Asia Pacific, and internationally. Xylem Inc. is headquartered in Rye Brook, New York.

Kratos Defense & Security Solutions, Inc. (KTOS) shares were down in last trading by -1.77% to $8.34. It experienced higher than average volume on day. The stock decreased in value by almost -3.92% over the past week and grew 5.84% in the past month. It is currently trading 7.24% above its 50 day moving average and 36.66% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -9.25% decrease in value from its one year high of $9.19. The RSI indicator value of 53.94, lead us to believe that it is a hold for now.

Kratos Defense & Security Solutions, Inc. provides mission critical products, solutions, and services primarily for the Government and commercial customers. The company operates through three segments, Kratos Government Solutions, Unmanned Systems, and Public Safety & Security. The Kratos Government Solutions segment offers microwave electronic products; satellite communications; technical and training solutions; modular systems; and defense and rocket support services. The Unmanned Systems segment provides unmanned aerial, ground, seaborne and command, control, and communications systems. The Public Safety & Security segment offers integrated solutions for homeland security, public safety, and critical infrastructure, as well as security and surveillance systems. This segment serves critical infrastructure, power generation, power transport, nuclear energy, financial, IT, healthcare, education, transportation, and petro-chemical industries, as well as government and military customers. The company was founded in 1994 and is headquartered in San Diego, California.

 

Stocks on Trader’s Radar: Geron Corporation (GERN), Threshold Pharmaceuticals, Inc. (THLD), Cara Therapeutics, Inc. (CARA)

Geron Corporation (GERN) continued its upward trend with the stock climbing 2.54% or $0.06 to close the day at $2.42 on active trading volume of 4.25M shares, compared to its three month average trading volume of 1.25M. The Menlo Park California 94025 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -10.7%, compared to the industry which has advanced 0.36% over the same period. With RSI of 72.23, the stock should still continue to rise and get closer to its one year target estimate of $4.38, making it a hold for now.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Threshold Pharmaceuticals, Inc. (THLD) climbed 15.48% during last trading as the stock added $0.1 to finish the day at $0.72 with about 4.1M shares changing hands, compared to its three month average trading volume of 795.03K. The $51.37M market cap company, which fluctuated between $0.6 and $0.734 during the day, currently situated 240.95% above its 52 week low of $0.21 and -51.62% away from its one year high of $1.48. The RSI of 79.48 indicates the stock is overbought at the current levels, sell for now.

Threshold Pharmaceuticals, Inc. discovers and develops therapeutic agents that target tumor cells for the treatment of cancer patients in the United States. Its lead investigational small molecule is evofosfamide, which is in two Phase III clinical trials for the treatment of soft tissue sarcoma indication and advanced pancreatic cancer; Phase II clinical trials for treating non-squamous non-small cell lung cancer; Phase II clinical trials for advanced melanoma; and Phase I/II clinical trials for multiple myeloma. The company is also involved in the study of evofosfamide in investigator sponsored trials, including Phase I/II clinical trials for glioblastoma; Phase I clinical trials for advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; Phase II clinical trials for glioblastoma and pancreatic neuroendocrine tumors; Phase I clinical trials for advanced solid tumors; and Phase I/II clinical trials for advanced kidney cancer or liver cancer. In addition, it engages in developing Tarloxotinib, a hypoxia-activated EGFR tyrosine kinase inhibitor, which is in two Phase II clinical trials for patients with advanced non-squamous non-small cell lung cancer, as well as patients with squamous cell carcinomas of the head, neck, or skin; and [18F]-HX4, an investigational PET imaging agent for hypoxia. The company has a license agreement with Merck KGaA to co-develop and commercialize evofosfamide; license agreement with Auckland UniServices Ltd. for the development program based on Tarloxotinib; and license agreement with Eleison Pharmaceuticals, Inc. for the manufacture, development, and commercialization of glufosfamide for the treatment of cancer in humans and animals, as well as other uses. It also has a collaboration with the National Cancer Institute to study TH-3424, a drug candidate for the treatment of cancer. Threshold Pharmaceuticals, Inc. was founded in 2001 and is headquartered in South San Francisco, California.

Cara Therapeutics, Inc. (CARA) saw its value increase by 14.95% as the stock gained $2.02 to finish the day at a closing price of $15.53. The stock was higher in trading and has fluctuated between $4.26-$17.2 per share for the past year. The shares, which traded within a range of $13.52 to $15.78 during the day, are up by 64.51% in the past three months and up by 136.74% over the past six months. It is currently trading 9.68% above its 20 day moving average and 34.37% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $21.75 a share over the next twelve months. The current relative strength index (RSI) reading is 60.72. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system. Its lead product candidate includes I.V. CR845, which is in Phase III clinical trials for the treatment acute postoperative pain in adult patients, as well as completed Phase II clinical trials for the treatment of uremic pruritus disease. The company is also developing Oral CR845, which is in Phase IIa clinical trials for the treatment of moderate-to-severe acute and chronic pain; and CR701, which is in preclinical trial stage for treating neuropathic and inflammatory pain. It has licensing agreements with Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize products containing CR845 in South Korea; and Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Shelton, Connecticut.

 

Stocks To Track: BorgWarner Inc. (BWA), Geron Corporation (GERN), Vista Outdoor Inc. (VSTO)

BorgWarner Inc. (BWA) climbed 0.1% during last trading as the stock added $0.04 to finish the day at $41.67 with about 2.29M shares changing hands, compared to its three month average trading volume of 2.25M. The $8.81B market cap company, which fluctuated between $41.39 and $42.18 during the day, currently situated 52.6% above its 52 week low of $27.52 and -0.74% away from its one year high of $42.18. The RSI of 60.66 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

BorgWarner Inc. provides solutions for combustion, hybrid, and electric vehicles worldwide. The company operates through two segments, Engine and Drivetrain. The Engine segment develops and manufactures turbochargers; and timing systems, such as timing chains, variable cam timing products, crankshaft and camshaft sprockets, tensioners, guides and snubbers, HY-VO front-wheel drive transmission chains, and four-wheel drive chains for light vehicles. It also provides emissions systems, including electric air pumps and exhaust gas recirculation (EGR) modules, EGR coolers, EGR tubes, and EGR valves; thermal systems products comprising viscous fan drives, polymer fans, and coolant pumps; and glow plugs, diesel cold start systems, and other gasoline ignition technologies. The Drivetrain segment develops and manufactures friction and mechanical products, including dual and friction clutch modules, friction and steel plates, transmission bands, torque converter clutches, one-way clutches, and torsional vibration dampers. This segment also offers control products comprising electro-hydraulic solenoids, transmission solenoid modules, and dual clutch control modules; torque management products, such as rear-wheel drive/all-wheel drive (AWD) transfer case systems, front wheel drive-AWD coupling systems, and cross-axle coupling systems; and starter motors, alternators, and hybrid electric motors. The company sells its products to original equipment manufacturers of light vehicles consisting of passenger cars, sport-utility vehicles, vans, and light trucks; commercial vehicles, such as medium-duty and heavy duty trucks, and buses; and off-highway vehicles, including agricultural and construction machinery, and marine applications, as well as to tier one vehicle systems suppliers and the aftermarket for light, commercial, and off-highway vehicles. BorgWarner Inc. was founded in 1987 and is headquartered in Auburn Hills, Michigan.

Geron Corporation (GERN) gained $0.18 to close the day at a new closing price of $2.36, a 8.26% increase in value from its previous closing price that moved the stock 30.39% above its 52 week low of $1.81. A total of 2.27M shares exchanged hands during the day compared with its three month average trading volume of 1.25M. The stock, which fluctuated between $2.17 and $2.38 during the day, currently situated -29.55% below its 52 week high. The stock is up by 12.92% in the past one month and up by 10.28% over the past three months. With a one year target estimate of $4.38 and RSI of 69.94, the stock still has upside potential, making it a hold for now.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Vista Outdoor Inc. (VSTO) had a active trading with around 2.26M shares changing hands compared to its three month average trading volume of 1.36M. The stock traded between $20.6 and $21.57 before closing at the price of $20.73 with -3.94% change on the day. The Farmington Utah 84025 based company is currently trading 5.12% above its 52 week low of $19.72 and -61.55% below its 52 week high of $53.91. Both the RSI indicator and target price of 19.29 and $33.25 respectively, lead us to believe that it could rise over the coming weeks.

Vista Outdoor Inc. designs, manufactures, and markets consumer products for the outdoor sports and recreation markets worldwide. The company’s Shooting Sports segment designs, develops, produces, and sources ammunition for the hunting and sport shooting enthusiast markets, as well as for local law enforcement, the United States government, and international markets under the Federal Premium, Speer, American Eagle, Blazer, CCI, Estate Cartridge, Stevens, Fusion, Savage Arms, Savage Range Systems, Force on Force, and Independence brands; and provides firearms products, such as centerfire rifles, rimfire rifles, shotguns, and range systems. Its Outdoor Products segment offers archery/hunting accessories, such as hunting arrows, game calls, hunting blinds, game cameras, and waterfowl decoys; eyewear and sport protection products comprising safety and protective eyewear, fashion and sports eyewear, and helmets; golf products, including laser rangefinders; and hydration products consisting of hydration packs and water bottles. This segment also offers optics products, such as binoculars, riflescopes, and telescopes; shooting accessories, including reloading equipment, clay targets, and premium gun care products; tactical products comprising holsters, duty gear, bags, and packs; and water sports products, such as stand up paddle boards. It provides its products under the Alliant Powder, Bee Stinger, BLACKHAWK!, Bollé, Bushnell, Butler Creek, CamelBak, Cébé, Champion Target, Eagle, Final Approach, Gold Tip, GunMate, Gunslick Pro, Hoppe’s, Jimmy Styks, M-Pro 7, Millett, Night Optics, Outers, Primos, RCBS, Redfield, Serengeti, Simmons, Stoney Point, Tasco, Uncle Mike’s, and Weaver brand names. The company sells its products to outdoor enthusiasts, hunters and recreational shooters, athletes, and law enforcement and military professionals through various mass, specialty, and independent retailers. The company was incorporated in 2014 and is headquartered in Farmington, Utah.

 

Stocks Buzz: McDermott International, Inc. (MDR), American Homes 4 Rent (AMH), Geron Corporation (GERN)

McDermott International, Inc. (MDR) managed to rebound with the stock declining 0% or $0 to close the day at $7.86 on light trading volume of 1.84M shares, compared to its three month average trading volume of 3.22M. The Houston Texas 77079 based company has been outperforming the oil & gas equipment & services group over the past 52 weeks, with the stock gaining 230.25%, compared to the industry which has advanced 39.26% over the same period. With RSI of 48.96, the stock should still continue to rise and get closer to its one year target estimate of $7.75, making it a hold for now.

McDermott International, Inc. provides engineering, procurement, construction and installation, and module fabrication services for upstream field developments worldwide. It operates through three segments: the Americas, Europe and Africa; the Middle East; and Asia. The company delivers fixed and floating production facilities, pipeline installations, and subsea systems from concept to commissioning for offshore and subsea oil and gas projects. Its operations include fabrication and offshore installation of fixed and floating structures; and the installation of pipelines and subsea systems, as well as provision of shallow water and deep water construction services. The company’s customers include national, integrated, and other oil and gas companies. McDermott International, Inc. was founded in 1923 and is headquartered in Houston, Texas.

American Homes 4 Rent (AMH) grew with the stock adding 0.66% or $0.15 to close at $22.84 on light trading volume of 1.83M compared its three months average trading volume of 2.28M. The Agoura Hills California 91301 based company operating under the REIT – Residential industry has been trending up for the last 52 weeks, with the shares price now 69.13% up for the period and up by 8.87% so far this year. With price target of $23.94 and a 75.43% rebound from 52-week low, American Homes 4 Rent has plenty of upside potential, making it a hold with a view buy.

American Homes 4 Rent is a real estate investment trust. The firm engages in the acquisition, renovation, leasing, and operating single-family home rental properties in the United States. American Homes 4 Rent was founded in 2012 and is based in Malibu, California.

Geron Corporation (GERN) managed to rebound with the stock climbing 3.37% or $0.07 to close the day at $2.15 on higher than average trading volume of 1.82M shares, compared to its three month average trading volume of 1.29M. The Menlo Park California 94025 based company has been outperforming the biotechnology companies by 13.7497% for last three months and its recent gains have pushed the stock slightly up 3.86% YTD, versus the biotechnology industry which is down -2.66% for the same period. The RSI of 57.75 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

 

Stocks In Queue: Geron Corporation (GERN), Hudson Pacific Properties, Inc. (HPP), Regal Entertainment Group (RGC)

Geron Corporation (GERN) climbed 2.96% during last trading as the stock added $0.06 to finish the day at $2.09 with about 1.36M shares changing hands, compared to its three month average trading volume of 1.32M. The $332.6M market cap company, which fluctuated between $2.04 and $2.1 during the day, currently situated 15.47% above its 52 week low of $1.81 and -37.61% away from its one year high of $3.35. The RSI of 53.44 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Hudson Pacific Properties, Inc. (HPP) gained $0.15 to close the day at a new closing price of $35, a 0.43% increase in value from its previous closing price that moved the stock 57.83% above its 52 week low of $22.77. A total of 1.36M shares exchanged hands during the day compared with its three month average trading volume of 1.54M. The stock, which fluctuated between $34.76 and $35.28 during the day, currently situated -4.5% below its 52 week high. The stock is down by -1.05% in the past one month and up by 9.83% over the past three months. With a one year target estimate of $39.2 and RSI of 46.95, the stock still has upside potential, making it a hold for now.

Hudson Pacific Properties, Inc. operates as a vertically integrated real estate trust (REIT) in the United States. It engages in owning, operating, and acquiring office, and media and entertainment properties primarily in Northern and Southern California in Los Angeles, Orange County, San Diego, San Francisco, Silicon Valley, and the East Bay. As of March 31, 2011, it owned a portfolio of 15 office properties; and 2 media and entertainment properties in California comprising approximately 4.4 million square feet. The company has elected to be treated as a REIT under the Internal Revenue Code of 1986. As a REIT, it would not be subject to federal income tax, provided it distributes at least 90% of its taxable income to its shareholders. The company is based in Los Angeles, California.

Regal Entertainment Group (RGC) had a light trading with around 1.36M shares changing hands compared to its three month average trading volume of 1.9M. The stock traded between $22.23 and $22.69 before closing at the price of $22.48 with 1.22% change on the day. The Knoxville Tennessee 37918 based company is currently trading 41.85% above its 52 week low of $16.84 and -8.44% below its 52 week high of $24.79. Both the RSI indicator and target price of 54.41 and $23.73 respectively, lead us to believe that it should be put on hold over the coming weeks.

Regal Entertainment Group, through its subsidiaries, operates as a motion picture exhibitor in the United States. It develops, acquires, and operates multi-screen theatres primarily in mid-sized metropolitan markets and suburban growth areas of larger metropolitan markets. The company operates a theatre circuit under the brands of Regal Cinemas, United Artists, Edwards, Great Escape Theatres, and Hollywood Theaters. As of January 6, 2017, it operated 7,310 screens in 565 theatres in 42 states along with Guam, Saipan, American Samoa, and the District of Columbia. Regal Entertainment Group was founded in 2002 and is based in Knoxville, Tennessee.

 

Stocks on Trader’s Radar: Geron Corporation (GERN), Hudson Pacific Properties, Inc. (HPP), Gigamon Inc. (GIMO)

Geron Corporation (GERN) failed to extend gains with the stock declining -2.4% or $-0.05 to close the day at $2.03 on active trading volume of 1.38M shares, compared to its three month average trading volume of 1.32M. The Menlo Park California 94025 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -31.42%, compared to the industry which has advanced 9.41% over the same period. With RSI of 50.18, the stock should still continue to rise and get closer to its one year target estimate of $4.38, making it a hold for now.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Hudson Pacific Properties, Inc. (HPP) fell -2.51% during last trading as the stock lost $-0.89 to finish the day at $34.52 with about 1.38M shares changing hands, compared to its three month average trading volume of 1.51M. The $5.05B market cap company, which fluctuated between $34.51 and $35.59 during the day, currently situated 55.66% above its 52 week low of $22.77 and -5.81% away from its one year high of $36.65. The RSI of 41.07 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Hudson Pacific Properties, Inc. operates as a vertically integrated real estate trust (REIT) in the United States. It engages in owning, operating, and acquiring office, and media and entertainment properties primarily in Northern and Southern California in Los Angeles, Orange County, San Diego, San Francisco, Silicon Valley, and the East Bay. As of March 31, 2011, it owned a portfolio of 15 office properties; and 2 media and entertainment properties in California comprising approximately 4.4 million square feet. The company has elected to be treated as a REIT under the Internal Revenue Code of 1986. As a REIT, it would not be subject to federal income tax, provided it distributes at least 90% of its taxable income to its shareholders. The company is based in Los Angeles, California.

Gigamon Inc. (GIMO) saw its value increase by 0.6% as the stock gained $0.2 to finish the day at a closing price of $33.35. The stock was higher in trading and has fluctuated between $21.23-$61.25 per share for the past year. The shares, which traded within a range of $32.5 to $33.75 during the day, are down by -39.69% in the past three months and down by -25.26% over the past six months. It is currently trading -14.62% below its 20 day moving average and -27.71% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $50.43 a share over the next twelve months. The current relative strength index (RSI) reading is 30.89. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Gigamon Inc. designs, develops, and sells products and services that provide customers with visibility and control of network traffic for enterprises and services providers in the United States, rest of Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers traffic visibility fabric solutions consisting of network traffic intelligence, such as controls for traffic selection, forwarding, manipulation, modification, de-duplication, SSL decryption, correlation, sampling, and generation of flow records. The company also provides Flow Mapping technology that identifies and directs incoming traffic to single or various tools based on user-defined rules that could be managed from a centralized management console; and GigaSMART platform, which offers a range of software applications to modify, manipulate, transform, filter, correlate, and sample network traffic. Its products include GigaVUE product family that provides end-user customers to design visibility fabric architectures optimized for a range of scale and performance requirements from monitoring in virtualized server environments, as well as to 1 gigabit appliances to multi-terabit chassis-based solutions. The company also offers ongoing technical support services with hardware and software products, including ongoing maintenance services for hardware and software, which enable the customers to receive ongoing software updates, bug fixes, and repairs; and replacement services for defective hardware. It sells its products directly through direct sales force and a network of channel partners. The company was founded in 2004 and is headquartered in Santa Clara, California.

 

Stocks Trend Analysis: Carrizo Oil & Gas, Inc. (CRZO), Geron Corporation (GERN), Eclipse Resources Corporation (ECR)

Carrizo Oil & Gas, Inc. (CRZO) managed to rebound with the stock climbing 1.81% or $0.66 to close the day at $37.14 on light trading volume of 1.14M shares, compared to its three month average trading volume of 1.31M. The Houston Texas 77002 based company has been outperforming the independent oil & gas group over the past 52 weeks, with the stock gaining 61.48%, compared to the industry which has advanced 53.65% over the same period. With RSI of 49.86, the stock should still continue to rise and get closer to its one year target estimate of $47.04, making it a hold for now.

Carrizo Oil & Gas, Inc., together with its subsidiaries, engages in the exploration, development, and production of oil and gas primarily in the United States. The company holds interests in oil and gas plays, including Eagle Ford Shale in Texas; the Delaware Basin in West Texas; the Utica Shale in Ohio; the Niobrara Formation in Colorado; and the Marcellus Shale in Pennsylvania. As of December 31, 2015, it had proved oil and gas reserves of 170.6 million barrels of oil equivalent; and operated 474 gross productive oil and gas wells. The company was founded in 1993 and is based in Houston, Texas.

Geron Corporation (GERN) retreated with the stock falling -1.55% or $-0.03 to close at $1.91 on light trading volume of 1.14M compared its three months average trading volume of 1.33M. The Menlo Park California 94025 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -38.39% down for the period and down by -7.73% so far this year. With price target of $4.38 and a 5.52% rebound from 52-week low, Geron Corporation has plenty of upside potential, making it a hold with a view buy.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Eclipse Resources Corporation (ECR) managed to rebound with the stock climbing 0.41% or $0.01 to close the day at $2.42 on lower than average trading volume of 1.14M shares, compared to its three month average trading volume of 1.23M. The State College Pennsylvania 16803 based company has been outperforming the independent oil & gas companies by -17.4945% for last three months and its recent losses have pulled the stock down -9.36% YTD, versus the independent oil & gas industry which is up 1% for the same period. The RSI of 39.15 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Eclipse Resources Corporation, an independent exploration and production company, acquires and develops oil and natural gas properties in the Appalachian Basin. The company owns interests in the Utica Shale and Marcellus Shale areas. As of December 31, 2015, it had an acreage position approximating 220,000 net acres in Eastern Ohio. The company’s estimated proved reserves consisted of 348.8 billion cubic feet of natural gas equivalent. Eclipse Resources Corporation was founded in 2011 and is headquartered in State College, Pennsylvania.

 

Traders Watch list: Range Resources Corporation (RRC), Geron Corporation (GERN), Tenet Healthcare Corp. (THC)

Range Resources Corporation (RRC) saw its value increase by 0.09% as the stock gained $0.03 to finish the day at a closing price of $34.23. The stock was lighter in trading and has fluctuated between $19.21-$46.96 per share for the past year. The shares, which traded within a range of $33.73 to $34.52 during the day, are down by -10.93% in the past three months and down by -22.35% over the past six months. It is currently trading -2.16% below its 20 day moving average and -1.6% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $47.69 a share over the next twelve months. The current relative strength index (RSI) reading is 47.85.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Range Resources Corporation operates as an independent natural gas, natural gas liquids (NGLs), and oil company. It engages in the exploration, development, and acquisition of natural gas and oil properties. The company holds interests in developed and undeveloped natural gas and oil leases in the Appalachian region of the United States. It owns and operates 4,462 net producing wells and approximately 905,000 net acres under lease in the Appalachian region; and 444 net producing wells and approximately 308,000 net acres under lease in the Texas Panhandle, as well as in the Anadarko Basin of western Oklahoma, the Nemaha Uplift of Northern Oklahoma and Kansas, the Permian Basin of West Texas, and Mississippi. The company markets and sells natural gas to utilities, marketing and midstream companies, and industrial users; NGLs to natural gas processors or users of NGLs; and oil and condensate to crude oil processors, transporters, and refining and marketing companies. As of December 31, 2015, it had proved reserves of 9.9 trillion cubic feet of natural gas equivalents. The company was formerly known as Lomak Petroleum, Inc. and changed its name to Range Resources Corporation in 1998. Range Resources Corporation was founded in 1975 and is headquartered in Fort Worth, Texas.

Geron Corporation (GERN) shares were up in last trading by 5% to $2.31. It experienced higher than average volume on day. The stock increased in value by almost 11.06% over the past week and grew 8.96% in the past month. It is currently trading 11.11% above its 50 day moving average and -9.17% below its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -46.53% decrease in value from its one year high of $3.95. The RSI indicator value of 65.44, lead us to believe that it is a hold for now.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Tenet Healthcare Corp. (THC) traded within a range of $16.21 to $16.81 after opening the day at $16.6. The company has seen its stock increase in value by 10.51% so far this year. The stock was down close to -1.2% on light volume in last trading session and closed at $16.4 per share. After the recent fall, the stock is currently holding -51.88% below its 52 week high of $34.08 and 16.64% above its 12-month low of $14.06. The shares are down by over -22.16% in the last three months, and the RSI indicator value of 54.61 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Tenet Healthcare Corp., together with its subsidiaries, primarily operates acute care hospitals and related healthcare facilities. The company operates through three segments: Hospital Operations and Other, Ambulatory Care, and Conifer. Its general hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive, critical, and coronary care units; physical therapy, orthopedic, oncology, and outpatient services; tertiary care services, including open-heart surgery, neonatal intensive care, and neurosciences; quaternary care services for heart, liver, kidney, and bone marrow transplants; quaternary pediatric and burn services; gamma-knife brain surgery; and cyberknife radiation therapy for tumors and lesions in the brain, lung, neck, and spine. In addition, it offers clinical research programs related to cardiovascular and pulmonary diseases, musculoskeletal disorders, neurological disorders, genitourinary diseases, and various cancers, as well as drug and medical device studies. Further, the company operates freestanding ambulatory surgery and imaging centers, short-stay surgical facilities, and Aspen’s hospitals and clinics. Additionally, it offers operational management for patient access, accounts receivable management, health information management, revenue integrity, and patient financial services; communications and engagement solutions; and clinical integration, financial risk management, and population health management services. As of December 31, 2015, the company operated 86 hospitals, 20 short-stay surgical hospitals, and approximately 475 outpatient centers; and 9 private hospitals and clinics, as well as 249 ambulatory surgery, 20 imaging, and 35 urgent care centers in the United Kingdom. Tenet Healthcare Corp. was founded in 1967 and is headquartered in Dallas, Texas.

 

3 Trending Stocks: Franklin Resources, Inc. (BEN), Geron Corporation (GERN), TEGNA Inc. (TGNA)

Franklin Resources, Inc. (BEN) managed to rebound with the stock climbing 0.5% or $0.2 to close the day at $40.48 on light trading volume of 1.36M shares, compared to its three month average trading volume of 3.2M. The San Mateo California 94403 based company has been outperforming the asset management group over the past 52 weeks, with the stock gaining 11.24%, compared to the industry which has advanced 9.02% over the same period. With RSI of 60.16, the stock should still continue to rise and get closer to its one year target estimate of $37.21, making it a hold for now.

Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.

Geron Corporation (GERN) climbed 5.39% during last trading as the stock added $0.11 to finish the day at $2.15 with about 1.35M shares changing hands, compared to its three month average trading volume of 1.34M. The $342.15M market cap company, currently situated 18.78% above its 52 week low of $1.81 and -58.25% away from its one year high of $5.15. The RSI of 54.44 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

TEGNA Inc. (TGNA) saw its value decrease by -0.99% as the stock dropped $-0.22 to finish the day at a closing price of $21.99. The stock was lighter in trading and has fluctuated between $17.91-$26.39 per share for the past year. The shares, which traded within a range of $21.85 to $22.2 during the day, are up by 3.63% in the past three months and up by 2.35% over the past six months. It is currently trading -1.71% below its 20 day moving average and 4.12% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $25.5 a share over the next twelve months. The current relative strength index (RSI) reading is 49.61. The technical indicator lead us to believe there will be no major movement any time soon, hold.

TEGNA Inc. engages in media and digital businesses in the United States. The company operates in two segments, Media and Digital. It operates 46 television stations that produce local programming, such as news, sports, and entertainment. The company also operates Cars.com, an online destination for automotive consumers that offers information about car shopping, selling, and servicing; CareerBuilder, which provides human capital solutions, such as employment data and labor market analysis software, talent management software, and other advertising and recruitment solutions; G/O Digital that provides digital marketing services for local businesses; and Cofactor, a digital marketing company that enable brands to deliver content. In addition, it offers advertising and marketing solutions. The company serves approximately 90 million customers through its broadcast and digital media platforms. The company was formerly known as Gannett Co., Inc. and changed its name to TEGNA Inc. in June 2015. TEGNA Inc. was founded in 1906 and is headquartered in McLean, Virginia.